Lung Cancer
From the Journals
Stereotactic body radiation therapy safe, effective for moderately central NSCLC
A stereotactic body radiation therapy regimen of 50 Gy given in five fractions had limited toxicity and yielded good survival in a cohort of...
From the Journals
Adding ramucirumab extends PFS in EGFR-mutated lung cancer
After a median follow-up of 20.7 months, the addition of ramucirumab was associated with a significantly better median PFS, at 19.4 months,...
From the Journals
Lazertinib has good showing in EGFR-mutated advanced NSCLC
Data for 127 patients treated at various doses showed that 54% had a response to the new third-generation EGFR TKI. Moreover, 44% of those with...
Opinion
The law of unintended consequences
Dr. Alan P. Lyss examines the impact of women’s health clinic closures and excessive radiation doses in some lung cancer screening programs.
Opinion
NSCLC: Predicting benefit from immunotherapy plus chemo
Dr. Alan P. Lyss reviews three studies presented at the World Conference on Lung Cancer on the use of tissue biomarkers in predicting the benefit...
Conference Coverage
Immunotherapy duo extends survival in first line for advanced NSCLC
BARCELONA – Nivolumab and low-dose ipilimumab improved survival of patients with untreated advanced non–small cell lung cancer regardless of PD-L1...
Conference Coverage
Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers
PHILADELPHIA – The findings support monitoring of cardiac biomarkers in the initial phase of checkpoint inhibitor treatment to identify patients...
Conference Coverage
Osimertinib improves survival in advanced NSCLC
BARCELONA – Osimertinib is the first TKI to show a survival advantage over another in advanced non–small cell lung cancer, FLAURA investigators...
Conference Coverage
CheckMate 817: Nivo+ipi shows safety, efficacy across stage IV NSCLC subgroups
BARCELONA – Combination nivolumab and ipilimumab showed good safety and encouraging clinical activity in patients with advanced NSCLC, despite...
Conference Coverage
OS benefit with pembrolizumab endures long-term in advanced NSCLC
BARCELONA – First-line pembrolizumab provides a durable long-term OS benefit, compared with that of chemotherapy, in patients with advanced...
Conference Coverage
PACIFIC: Patterns of lung cancer progression suggest role for local ablative therapy
Approximately two-thirds of patients with distant progression had one or two new lesions.